Previous Close | 2.8600 |
Open | 2.7800 |
Bid | 2.8600 x 1000 |
Ask | 2.9100 x 1400 |
Day's Range | 2.7800 - 2.9550 |
52 Week Range | 1.5700 - 34.3500 |
Volume | |
Avg. Volume | 46,048 |
Market Cap | 90.071M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6740 |
Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Apr 23, 2008 |
1y Target Est | 32.50 |
CAMBRIDGE, Mass., December 21, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, announced today that the company will present at the 6th Annual Neuroscience Forum and the Biotech Showcase™. Both events will be held live and are scheduled to coincide with the 41st Annual J.P. Morgan Health Care Conference in San Francisco
CAMBRIDGE, Mass., November 28, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC’) for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos
CAMBRIDGE, Mass., November 16, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced that Avani Kanubaddi, President & COO of Enveric Biosciences, will participate in A.G.P.’s Virtual Biotech Conference to be held from November 30, 2022 – December 1, 2022.